| |
| |
|
| Insider
Information: |
Tananbaum James B. |
| Relationship: |
10% Owner |
| City: |
San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
9 |
|
| Direct
Shares |
1,064,512 |
|
|
Indirect Shares
|
33,413,451 |
|
|
| Direct
Value |
$18,101,670 |
|
|
|
Indirect Value
|
$422,060,439 |
|
|
| Total
Shares |
34,477,963 |
|
|
| Total
Value |
$440,162,109 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
9
|
1
|
|
Stock
price went up :
|
8
|
0
|
| Stock
price went down : |
1
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
8.0
|
-1.0
|
| Percentage
Gain/Loss : |
 36.0%
|
 -23.5%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Aimmune Therapeutics, Inc. |
AIMT |
10% Owner |
2015-08-11 |
0 |
2016-08-18 |
4,902,920 |
Premium* |
|
|
Aerie Pharmaceuticals Inc |
AERI |
10% Owner |
2016-07-22 |
0 |
2020-02-27 |
1,229,633 |
Premium* |
|
|
10x Genomics, Inc. |
TXG |
10% Owner |
2019-09-12 |
0 |
2020-05-13 |
2,677,383 |
Premium* |
|
|
Disc Medicine, Inc |
IRON |
Director |
2020-08-14 |
441,500 |
2021-02-05 |
3,370,250 |
Premium* |
|
|
Kinnate Biopharma Inc. |
KNTE |
|
2020-12-07 |
0 |
2024-04-03 |
0 |
Premium* |
|
|
Aclaris Therapeutics, Inc. |
ACRS |
10% Owner |
|
0 |
2021-11-01 |
4,665,553 |
Premium* |
|
|
Pardes Biosciences Ord Shs |
PRDS |
Director, 10% Owner |
2021-02-19 |
602,500 |
2023-04-05 |
13,583,762 |
Premium* |
|
|
Highcape Capital Acquisition Corp. |
QSI |
Director |
2021-06-11 |
20,512 |
2021-06-10 |
1,598,125 |
Premium* |
|
|
Theseus Pharmaceuticals, Inc. |
THRX |
10% Owner |
|
0 |
2023-07-17 |
1,385,825 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| KNTE |
Kinnate Biopharma Inc. |
|
– • • |
2024-04-03 |
4 |
D |
$0.00 |
$0 |
I/I |
(13,718,311) |
0 |
0 |
- |
|
| THRX |
Theseus Pharmaceuticals, ... |
10% Owner |
– – • |
2023-07-17 |
4 |
B |
$2.97 |
$2,079,000 |
I/I |
700,000 |
1,385,825 |
1.5 |
- |
|
| KNTE |
Kinnate Biopharma Inc. |
Director |
– • • |
2023-05-08 |
4 |
B |
$2.80 |
$4,984,000 |
I/I |
1,780,000 |
520,711 |
2.25 |
- |
|
| PRDS |
Pardes Biosciences Ord Sh... |
Director |
– • • |
2023-04-05 |
4 |
B |
$1.50 |
$1,160,928 |
I/I |
773,952 |
13,583,762 |
2.25 |
- |
|
| PRDS |
Pardes Biosciences Ord Sh... |
Director |
– • • |
2023-04-05 |
4 |
B |
$1.50 |
$1,160,928 |
I/I |
773,952 |
8,773,134 |
2.25 |
- |
|
| KNTE |
Kinnate Biopharma Inc. |
Director |
– • • |
2023-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
1,100,000 |
1,975,001 |
0 |
- |
|
| THRX |
Theseus Pharmaceuticals, ... |
10% Owner |
– – • |
2022-12-29 |
4 |
B |
$5.00 |
$2,500,000 |
I/I |
500,000 |
1,209,275 |
1.5 |
- |
|
| THRX |
Theseus Pharmaceuticals, ... |
10% Owner |
– – • |
2022-06-09 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,294,621 |
|
- |
|
| ACRS |
Aclaris Therapeutics, Inc... |
10% Owner |
– – • |
2021-11-01 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,954,904) |
0 |
0 |
- |
|
| ACRS |
Aclaris Therapeutics, Inc... |
10% Owner |
– – • |
2021-11-01 |
4 |
A |
$0.00 |
$0 |
I/I |
8,276 |
8,276 |
0 |
- |
|
| QSI |
Highcape Capital Acquisit... |
Director |
– • – |
2021-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
20,512 |
20,512 |
0 |
- |
|
| QSI |
Highcape Capital Acquisit... |
Director |
– • – |
2021-06-10 |
4 |
A |
$0.00 |
$25,000,696 |
I/I |
8,403,805 |
1,598,125 |
0 |
- |
|
| PRDS |
Pardes Biosciences Ord Sh... |
President & CEO |
• • • |
2021-02-19 |
4 |
B |
$10.00 |
$6,025,000 |
D/D |
602,500 |
602,500 |
3.23 |
% |
|
| ACRS |
Aclaris Therapeutics, Inc... |
10% Owner |
– – • |
2021-02-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
6,612,181 |
|
% |
|
| IRON |
Disc Medicine, Inc |
Director |
– • – |
2021-02-05 |
4 |
A |
$0.00 |
$0 |
I/I |
2,928,750 |
2,928,750 |
0 |
- |
|
| IRON |
Disc Medicine, Inc |
Director |
– • – |
2021-02-05 |
4 |
A |
$10.00 |
$15,000,000 |
I/I |
1,500,000 |
1,500,000 |
0 |
- |
|
| KNTE |
Kinnate Biopharma Inc. |
|
• • • |
2020-12-07 |
4 |
A |
$0.00 |
$0 |
I/I |
9,838,311 |
291,667 |
0 |
- |
|
| IRON |
Disc Medicine, Inc |
President & CEO |
• • • |
2020-08-14 |
4 |
B |
$10.00 |
$4,415,000 |
D/D |
441,500 |
441,500 |
3.23 |
- |
|
| TXG |
10x Genomics, Inc. |
10% Owner |
– – • |
2020-05-13 |
4 |
S |
$80.13 |
$116,188,500 |
I/I |
(1,450,000) |
2,350,000 |
0 |
- |
|
| TXG |
10x Genomics, Inc. |
10% Owner |
– – • |
2020-05-12 |
4 |
A |
$0.00 |
$0 |
I/I |
1,930,198 |
4,300,000 |
0 |
- |
|
| TXG |
10x Genomics, Inc. |
10% Owner |
– – • |
2020-05-06 |
4 |
A |
$0.00 |
$0 |
I/I |
2,000,000 |
3,000,000 |
0 |
- |
|
| TXG |
10x Genomics, Inc. |
10% Owner |
– – • |
2020-04-23 |
4 |
A |
$0.00 |
$0 |
I/I |
1,000,000 |
1,869,802 |
0 |
- |
|
| TXG |
10x Genomics, Inc. |
10% Owner |
– – • |
2020-04-22 |
4 |
A |
$0.00 |
$0 |
I/I |
270,842 |
327,383 |
0 |
- |
|
| TXG |
10x Genomics, Inc. |
10% Owner |
– – • |
2020-04-22 |
4 |
D |
$0.00 |
$0 |
I/I |
(878,584) |
0 |
0 |
- |
|
| TXG |
10x Genomics, Inc. |
10% Owner |
– – • |
2020-04-14 |
4 |
A |
$0.00 |
$0 |
I/I |
1,500,000 |
1,500,000 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
